We conducted a randomized, double-blind, placebo-controlled multicenter trial of azithromycin (1,200 mg once weekly) for the prevention of Mycobacterium avium complex (MAC) infection in patients with AIDS and a CD4 cell count of õ100/mm 3 . In an intent-to-treat analysis through the end of therapy plus 30 days, nine (10.6%) of 85 azithromycin recipients and 22 (24.7%) of 89 placebo recipients developed MAC infection (hazard ratio, 0.34; P Å .004). There was no difference in the ranges of minimal inhibitory concentrations of either clarithromycin or azithromycin for the five breakthrough (first) MAC isolates from the azithromycin group and the 18 breakthrough MAC isolates from the placebo group. Of the 76 patients who died during the study, four (10.5%) of 38 azithromycin recipients and 12 (31.6%) of 38 placebo recipients had a MAC infection followed by death (P Å .025). For deaths due to all causes, there was no difference in time to death or number of deaths between the two groups. Episodes of non-MAC bacterial infection per 100 patient years occurred in 43 azithromycin recipients and 88 placebo recipients (relative risk, 0.49; 95% confidence interval, 0.33 -0.73). The most common toxic effect noted during the study was gastrointestinal, reported by 78.9% of azithromycin recipients and 27.5% of placebo recipients. Azithromycin given once weekly is safe and effective in preventing disseminated MAC infection, death due to MAC infection, and respiratory tract infections in patients with AIDS and CD4 cell counts of õ100/mm 3 .
Mycobacterium avium complex (MAC) infection is the most antiretroviral regimens and prophylaxis for pneumocystis infection, the incidence of MAC infection has progressively incommon cause of bacterial opportunistic infections in persons with AIDS in the United States [1] . After a diagnosis of AIDS, creased.
The survival of patients with MAC infection is shorter (107 -the incidence of MAC bacteremia was found to be 21% at 1 year and 43% at 2 years when monthly lysis centrifugation 139 days) than that of patients with AIDS but without MAC infection (275 -330 days) [4 -6] . As would be expected from blood cultures were routinely performed [2] . Among those patients with a CD4 cell count of õ50/mm 3 , the incidence is the increasing incidence of MAC infection, the rate of deaths due to MAC infection in patients with AIDS has also increased even higher: 32% at 6 months and 51% at 1 year [3] . As the survival of patients with AIDS has increased with improved from 6.7% in 1987 to 12.2% in 1992 [7] . With the availability of the macrolides and effective combination therapy, survival after a diagnosis of MAC infection has increased from 4.5 months without treatment to Ç9 months rifabutin has been a significant advance in prophylaxis for
Patients were randomly assigned in a one-to-one ratio by a computer-generated random code in blocks of four to receive MAC infection, its efficacy is only modest, and there are a number of drawbacks, including the numerous potential drug either azithromycin or placebo. Azithromycin was given as four 300-mg lactose-free tablets in a single dose once each interactions, high cost, problems with compliance associated with daily therapy, and the potential of Mycobacterium tuberweek 1 hour before or 2 hours after a meal. The placebo was an identical-appearing lactose-free tablet. culosis to produce cross-resistance to rifampin.
Azithromycin is an azalide differing from erythromycin only Efficacy and safety were evaluated monthly in terms of signs or symptoms of MAC infection, adverse events, and intercurat the 9 position of the macrolide ring. Serum levels are low (0.4 mg/mL after a 500-mg dose [11] ), and activity against rent illnesses. A blood specimen for MAC culture was obtained at each monthly visit. Compliance was evaluated, and a calen-MAC in vitro has been modest. In a study of 15 MAC strains, the MIC 90 was 64 mg/mL, while all bactericidal values were dar was used to keep a record of the day and date of each weekly dose. CD4 cell counts were determined every 6 months, ú64 mg/mL [12] . However, azithromycin achieves tissue levels that are 10-to 200-fold higher than serum levels with a proand laboratory safety tests were performed monthly for 2 months and then bimonthly. Binaural audiograms were to be longed half-life of 3 days. The concentration in macrophages, the site of replication of MAC, is ú500-fold higher than serum obtained within 1 month of the baseline visit, within 4 weeks of the final dose of study drug, and for any subject reporting levels [13] . Azithromycin monotherapy (500 mg/d) for patients with AIDS and MAC bacteremia resulted in a 1.3 log reduction hearing loss during the study. Blood specimens for MAC cultures were collected in 8.3-in MAC cfu/mL in blood cultures and resolution of fever and sweats in two-thirds of patients [14] . mL sterile yellow top vacutainers (Becton Dickinson, Sparks, MD) containing sodium polyanetholesulfonate and were Because of the favorable pharmacokinetics, which allow once weekly dosing, and encouraging results of therapy for MAC shipped to the National Jewish Center for Immunology and Respiratory Medicine in Denver for processing. The theoretical infection in humans, we undertook a study of azithromycin for prevention of MAC infection in patients with AIDS and a CD4 limit of detection was one viable organism per 8.3 mL of blood. Culture was performed in 7H12 BACTEC vials (Becton lymphocyte count of õ100/mm 3 . This placebo-controlled trial is a companion study to the comparative trial of azithromycin Dickinson), and the number of cfu/mL was quantified on plates with 7H11 agar. Identification to the species level was pervs. rifabutin vs. azithromycin plus rifabutin [15] .
formed by a DNA-RNA hybridization technique (Gen-Probe, San Diego). MICs of clarithromycin and azithromycin were Methods determined on Mueller-Hinton agar (pH 7.4) and in 7H12 broth (pH 7.4) [16] .
Study Design
The primary study end points were the development of MAC infection documented by culture of a specimen from a sterile We conducted a randomized, double-blind, placebo-controlled multicenter trial of once weekly azithromycin for the tissue site, MAC bacteremia, or MAC infection -related symptoms including fever, night sweats, diarrhea, or weight loss prevention of MAC infection in patients with AIDS. Men and nonpregnant women who were HIV-seropositive and 18 years unexplained by other etiologies and sufficient to warrant empirical therapy for MAC infection. The secondary study end points of age or older were eligible for the study. Subjects had to have had one documented CD4 cell count of õ100/mm 3 within were the development of non-MAC bacterial infections (sinusitis, pneumonitis, bacteremia, and soft-tissue infection). The the preceding 12 months. Two blood specimens for MAC cultures were obtained, one at the screening visit and one at 3 -bacterial infections were defined by the investigators, and a positive culture (except for bacteremia) was not required. 5 weeks after the baseline visit.
Criteria for exclusion included a positive blood culture for Patients were to remain in the study for at least 18 months. Patients continued to receive the study drug weekly until they MAC at screening or baseline, symptoms suggestive of MAC infection (including unexplained diarrhea, fever, or night reached a primary study end point or died, unless they had treatment-related side effects or abnormalities revealed by labosweats), a history of MAC infection, or known or suspected M. tuberculosis infection. Subjects treated in the 4 weeks before ratory studies that required study withdrawal, had an intercurrent infection requiring ú4 weeks of therapy with a drug active enrollment with any putative therapy for MAC infection or who had a known hypersensitivity to macrolides also were against MAC, or had progression of AIDS to the extent that the subject's disabilities precluded study continuation. Lack of excluded. Subjects for whom screening laboratory tests revealed values for aminotransferases and alkaline phosphatase compliance to the extent that a subject consistently failed to take ú50% of the doses of study drug or attended õ50% of the that were greater than five times the upper limit of normal, a total bilirubin level of ú2.5 mg/dL, a creatinine level of ú2.5 monthly follow-up visits was also a reason for study withdrawal. mg/dL, or a neutrophil count of õ0.50 1 10 9 /L were excluded.
Statistical Analysis
The protocol was approved by the Institutional Review Board at each of the participating centers. Informed consent Sample size was based on an incidence of MAC bacteremia of 25% among the placebo group in 18 months. With 75 subwas obtained from each study subject before enrollment.
/ 9c48$$mr05 02-11-98 17:49:32 cidal UC: CID Primary analyses were based on time to the event. Cox regression (proportional hazards model) was used to generate a P value and a hazard ratio (HR) for time to the event with 95% confidence intervals (SAS PROC PHREG, SAS Institute, whom blood cultures were positive for MAC at the baseline visit were also excluded from the ITT analysis. Three placebo Cary, NC). The Kaplan-Meier product limit method was used to generate a log rank, and a generalized Wilcoxon test was recipients received the study drug for õ30 days and were excluded from the evaluable analysis. Therefore, there were used to calculate time to the event.
The data capture window for symptoms associated with a 85 and 86 patients in the azithromycin and placebo groups, respectively. MAC end point was from 60 days before the event through 30 days after the event. For the laboratory tests, the closest
The baseline characteristics were similar between the two groups (table 1). Most patients were males from 24 to 44 years assessment within 180 days before the event or 90 days after the event was used.
of age. The mean weight was 71.7 kg (range, 48 -100 kg) for the azithromycin group and 70.6 kg (range, 46 -103 kg) for the A predetermined interim analysis was performed in August 1994 at an a value of .001. Results for time to the MAC placebo group. The mean values for hemoglobin and alkaline phosphatase were similar at baseline, as were the median CD4 event showed superiority of azithromycin over placebo at the significance level of P £ .05 but not at the prespecified level cell counts (43.9 vs. 44.3/mm 3 in the azithromycin and placebo groups, respectively). The use of antiretroviral agents, prophyof P £ .001. Because of the interim analysis, statistical significance was judged at an a value of .049 to maintain an overall laxis for pneumocystis infection, and baseline opportunistic infections were also generally comparable between the two significance of .05. All P values were two-sided.
Additional sensitivity analyses were performed to determine groups (table 2) . The mean duration of therapy was 400 days (range, 30 -985 the consistency of the primary analysis under other conditions. Covariate adjustments for the analysis of time to the MAC days) for the azithromycin group and 340 days (range, 36 -1018 days) for the placebo group. The study was terminated event included stratification by center and baseline CD4 cell count.
early by the sponsor in May 1995 on the basis of a preliminary review of data from a separate study that raised ethical concerns for the placebo group. At the time of study termination, the Results most recently enrolled subject had been in the study for 8.5 months, and 120 subjects had met the predetermined study to-treat analysis through the last study follow-up visit (ITT-2) for Dapsone 15 21 prophylaxis with once weekly azithromycin ( -) vs. placebo (---).
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The hazard ratio of bacteremia in the azithromycin group as compared with the placebo group was 0.41 (95% CI, 0.21 -0.79; P Å .006).
NOTE. Some patients received more than one antiretroviral or prophylactic agent during the study period.
cultures (bone marrow and cystic [gallbladder] lymph node, respectively). In the ITT-1 analysis, there was one additional In the ITT-1 analysis (through 30 days after completion of therapy), nine (10.6%) of 85 azithromycin recipients vs. 22 blood culture positive for MAC in each group. In addition, there was one azithromycin recipient for whom bone marrow (24.7%) of 89 placebo recipients developed disseminated MAC infection (HR, 0.34; P Å .004). In the ITT-2 analysis (through biopsy revealed granulomas but culture was negative and there was one placebo recipient for whom stool culture was positive the last follow-up visit), 13 (15.3%) of 85 azithromycin recipients vs. 27 (30.3%) of 89 placebo recipients developed dissemfor MAC. Both of these patients were symptomatic. In the ITT-2 analysis, there were three additional empirical diagnoses (two inated MAC infection (HR, 0.41; P Å .006) (figure 1). The absolute risk reduction for MAC infection in the evaluable azithromycin recipients and one placebo recipient); the remaining diagnoses were based on blood or bone marrow culgroup by azithromycin therapy was 15.1%, with a relative risk reduction of 65%. The number of treated patients needed to tures positive for MAC. For those patients in the evaluable group who developed MAC infection, the median time to diagprevent one case of disseminated MAC infection was 6.6.
The diagnosis of disseminated MAC infection was based on nosis was 269 days in the azithromycin group compared with 169 days in the placebo group. blood cultures positive for MAC in 25 of the 27 episodes in the evaluable group. The mean cfu/mL was 1.0 for the When the occurrence of disseminated MAC infection was stratified by baseline CD4 cell count, the greatest risk reduction azithromycin group and 3.5 for the placebo group. One patient in the azithromycin group and one patient in the placebo group was provided for the lowest quartile of CD4 cell counts (CD4 cell count, £24/mm 3 ). In this group, two (6.5%) of 31 azithrohad a clinical syndrome consistent with disseminated MAC infection and positive acid-fast staining of tissue but negative mycin recipients vs. 10 (33.3%) of 30 placebo recipients devel- oped disseminated MAC infection (RR, 0.19; 95% CI, 0.06 -33.7%, respectively) was lower among the azithromycin group than among the placebo group. These differences were not 0.66). In the group with CD4 cell counts of 25 -49/mm 3 , three (13.6%) of 22 azithromycin recipients and seven (28%) of 25 statistically significant; however, the power to detect a difference of 20% at an a value of .05 was only 11.9%. placebo recipients developed disseminated MAC infection (RR, 0.48; 95% CI, 0.15 -2.08). Of note, five (18.5%) of the For the patients who died, there was a trend for the median time from the baseline visit to death to be longer (462 vs. 357 27 cases of MAC bacteremia occurred in subjects with a CD4 cell count of ú50/mm 3 at baseline. days, respectively) and the time from diagnosis of disseminated MAC infection to death to be longer (287 vs. 187 days, respecAlmost all patients in both groups who developed disseminated MAC infection were symptomatic during a period from tively) for the azithromycin group than for the placebo group. However, none of these comparisons reached statistical sig-60 days before the MAC event to 30 days after the event. In the evaluable group, all seven azithromycin recipients who nificance. For deaths due to all causes, the results were similar for the two groups (figure 2). For the evaluable group, 11 developed MAC infection had fever and night sweats, and five of seven had weight loss of ú5% of the baseline weight. In (12.9%) of 85 azithromycin recipients died vs. 10 (11.6%) of 86 placebo recipients (HR, 1.04; P Å .92). In the ITT-1 analythe placebo group, 19 of 20 patients had fever, night sweats, or weight loss. sis, 13 (15.3%) of 85 azithromycin recipients died vs. 11 (12.4%) of 89 placebo recipients (HR, 1.02; P Å .955). For the two groups as a whole, the mean percentage of visits at which an individual patient complained of fever was lower for azithromycin recipients than for placebo recipients (9.6% vs. 16.5%, respectively; P õ .05).
Other Infections
For non-MAC bacterial infections, there were significantly fewer episodes of sinusitis (12 vs. 30 episodes per 100 patient
Drug Susceptibility
Of the breakthrough (first) MAC isolates, five from azithromycin recipients and 18 from placebo recipients were available for determination of susceptibility to azithromycin and clarithromycin. The MICs of azithromycin were £64 mg/mL on Mueller-Hinton agar and £32 mg/mL in 7H12 broth for all isolates. The MICs of clarithromycin were £4 mg/mL on Mueller-Hinton agar and £2 mg/mL in 7H12 broth for all isolates. The range of MICs was similar between the isolates from azithromycin and placebo recipients (table 4).
Survival
Through the last follow-up visit, there were 38 deaths in each group. Of the patients who died, four (10.5%) of 38 There were two premature withdrawals from the study because during the study. However, both withdrawals were thought to * Refers to relative risk of infection while receiving azithromycin compared be unrelated to the study drug by the blinded investigators. For with placebo.
subjects with neutrophil counts within normal limits at baseline, counts of £500/mm 3 were seen in two (8%) of 25 azithromycin recipients compared with none of 26 placebo recipients. years, respectively) and pneumonia (3 vs. 18 episodes per 100
During the study, three azithromycin recipients and four patient years, respectively) in the azithromycin group than in placebo recipients complained of new hearing loss. One of the the placebo group (table 5) . For soft-tissue infections and bacazithromycin recipients and all four of the placebo recipients teremia, there was a nonsignificant trend toward fewer events had objective hearing loss on binaural audiograms (decrease in the azithromycin group than in the placebo group.
in air conduction levels of §10 dB). An equal number of There were three cases of toxoplasmosis and two cases of patients in each group complained of new onset tinnitus. Overcryptosporidiosis diagnosed during the study in the placebo all, new or increased objective findings were noted on binaural group. There were no new diagnoses of either opportunistic audiograms for 15 patients in each group. infection in the azithromycin group.
Although all patients were receiving prophylaxis for PneuDiscussion mocystis carinii pneumonia (PCP), azithromycin recipients had 11.5 episodes of PCP per 100 patient years compared with 17. 2 We conducted a randomized, double-blind, placebo-conepisodes per 100 patient years in the placebo group (HR, 0.66; trolled multicenter trial that demonstrated that azithromycin 95% CI, 0.29 -1.52). Among those azithromycin recipients who (1,200 mg once a week) can significantly decrease the incidence were not receiving therapy with a sulfonamide (trimethoprimof disseminated MAC infection. The absolute risk reduction sulfamethoxazole or dapsone), the incidence of PCP was 7.5 of disseminated MAC infection associated with azithromycin episodes per 100 patient years compared with 78.6 episodes prophylaxis was 15.1% (incidence of disseminated MAC infecper 100 patient years in the placebo group (HR, 0.09; 95% CI, tion, 23.3% among the placebo group vs. 8.2% among the 0.01 -0.75; P Å .026).
azithromycin group). The relative risk reduction was 65%. This effect was statistically significant whether the analysis was based on the actual treatment received (evaluable group) or on Adverse Events and Laboratory Abnormalities the randomized treatment (ITT analysis). The reduction of the incidence of disseminated MAC infection was seen whether During the study, the most frequent toxic effect was gastrointestinal. At least one episode of a gastrointestinal toxic effect the analysis was limited to 30 days after the last dose of the study drug (ITT-1 analysis) or through the last follow-up visit that was thought to be related to the study drug occurred in 71 (78.9%) of 90 azithromycin recipients and in 25 (27.5%) of (ITT-2 analysis). Two other medications, rifabutin and clarithromycin, have 91 placebo recipients. In the azithromycin group, 52.2% of the patients had diarrhea, 32.2% had nausea, 26.7% had abdominal been shown to significantly decrease the incidence of MAC infections. In two large multicenter trials, rifabutin decreased pain, and 6.7% had nausea associated with the study drug at least once during the study. Most of these events were mild to the incidence of MAC infections by 50% and was associated with a nonsignificant trend toward a decrease in the number moderate and well tolerated. However, 6.6% of the abdominal pain episodes, 4.4% of the diarrheal episodes, and 2.2% of the of deaths due to all causes [9] . However, subsequent comparative trials with both azithromycin and clarithromycin have nausea episodes were rated as severe by the patients.
Seven azithromycin recipients (8.2%) withdrew from the shown that the macrolides are superior for the prevention of MAC infections [15, 17] . Further decreasing its more universal study because of drug intolerance (six, gastrointestinal intolerance; one, rash), and two placebo recipients (2.3%) withdrew acceptance as a prophylactic agent is the potential of M. tuber-/ 9c48$$mr05 02-11-98 17:49:32 cidal UC: CID culosis to produce cross-resistance to rifampin [18] . Currently, was noted in the study by Havlir et al. [15] , in which only two (11%) of 18 isolates were resistant to macrolides. the U.S. Public Health Service recommends either clarithromycin or azithromycin as the preferred prophylactic agent for
The development of macrolide resistance during prophylaxis is a critical issue as the macrolides serve as the backbone of prevention of MAC infections [19] .
Clarithromycin at a dosage of 500 mg twice a day appears effective therapy for disseminated MAC infection. The U.S. Public Health Service has recommended that combination therto be highly effective in preventing MAC infection. A large multicenter trial revealed a 69% reduction in the incidence of apy should always include a macrolide. Since there is essentially complete cross-resistance between azithromycin and cla-MAC infections and a significant survival benefit when clarithromycin prophylaxis was compared with placebo [20] . Of rithromycin [21] , loss of susceptibility by MAC due to prophylaxis with one macrolide would result in a marked reducmajor concern was the fact that 11 (57.9%) of 19 of the breakthrough isolates were resistant to clarithromycin. Because there tion in the efficacy of any subsequent treatment of disseminated MAC infection. has been almost universal cross-resistance between clarithromycin and azithromycin [21] , these isolates may prove unreIn this study, prophylaxis with azithromycin did reduce the number of deaths preceded by MAC infection; however, it did sponsive to subsequent macrolide therapy, which is currently the cornerstone of effective therapy for MAC infection.
not reduce the number of deaths due to all causes. Of the evaluable group, 11 of 85 azithromycin recipients died, and 10 A comparison of the placebo-controlled trial of clarithromycin [20] and the current study is made difficult by the use of 86 placebo recipients died. The study design may have made the detection of a difference in mortality more difficult as this of different end points and statistical analyses. However, if a comparable statistical analysis (intention to treat through the study was, from a practical standpoint, a comparison of close monitoring, of routine monthly blood cultures for early diagnolast follow-up) is performed and comparable end points (culture-positive cases only) are used, the reduction in risk of MAC sis of MAC, and of rapid institution of macrolide therapy vs. azithromycin prophylaxis. The study conditions were clearly infection is quite similar for azithromycin and clarithromycin (73% and 69%, respectively).
different from routine clinical practice and may have made it more difficult to demonstrate an impact on mortality. Despite The most profound impact of azithromycin on the prevention of disseminated MAC infection was in the group of patients these circumstances, there was a trend to an increase in the time from study baseline to death (462 vs. 357 days) as well with a CD4 cell count of õ25/mm 3 at baseline, for whom a fivefold reduction in the incidence of disseminated MAC events as a nonstatistically significant trend to lower mortality at 12 and 18 months for the azithromycin group. was seen. A twofold reduction in the incidence of disseminated MAC infection was seen among patients with CD4 cell counts
The effect of azithromycin prophylaxis on deaths due to all causes cannot be answered by this study because it was powfrom 25 to 49/mm 3 . Of note, 18.5% of all episodes of MAC bacteremia occurred in patients with a CD4 cell count of ered only to detect a difference in MAC events. The study had only an 11.9% power to detect a 20% reduction in the number ú50/mm 3 at baseline. Some investigators have reported that MAC bacteremia may of deaths due to all causes at 18 months. We noted a significant reduction in the incidence of prebe detected transiently without association with clinical disease [22] . In this study, 100% of the azithromycin recipients and sumed non-MAC bacterial infections in the azithromycin group, specifically pneumonia and sinusitis. These results are 80% of the placebo recipients who developed MAC bacteremia had fever, night sweats, or weight loss during a period from consistent with the excellent activity of azithromycin against the most common respiratory tract pathogens and success in the 60 days before the MAC event to 30 days after the event.
The azithromycin failures may be due to poor drug absorptreatment of these clinical entities that has been demonstrated in numerous comparative clinical trials [11] . tion, noncompliance, drug resistance, or as yet undefined reasons. The actual cause of azithromycin failures remains unclear, Although there were too few episodes of PCP in this trial to demonstrate a statistically significant reduction in the numbut development of resistance does not appear to be the reason. Although the number of isolates was small and the results will ber of all cases of PCP, there was a significant reduction in the incidence of PCP by azithromycin prophylaxis for those clearly need confirmation with testing of more breakthrough isolates, there was no resistance noted in the isolates from patients who were not receiving trimethoprim-sulfamethoxazole or dapsone. This reduction in the incidence of PCP is patients receiving azithromycin. The MICs of clarithromycin for all five breakthrough isolates from azithromycin recipients consistent with findings from another study of azithromycin prophylaxis in which the incidence of PCP was 13% among were £4 mg/mL on Mueller-Hinton agar and £1 mg/mL in 7H12 broth, findings consistent with the MICs for wild-type the placebo group and 8.7% among the azithromycin group (HR, 0.56; P Å .045) [23] . isolates that have never been exposed to clarithromycin [16] . The MICs of clarithromycin for breakthrough isolates recov-
The most frequent drug-related toxic effect was gastrointestinal, a finding consistent with the well-described activity of ered during treatment of patients with disseminated MAC infection whose conditions are clinically worsening consistently are azithromycin and other macrolides as agonists of motilin (which directly enhances gastric contractions). This finding ú256 mg/mL [21] . A similar low rate of resistance in breakthrough isolates recovered during azithromycin prophylaxis is also consistent with data for 3,995 patients who received / 9c48$$mr05 02-11-98 17:49:32 cidal UC: CID
